Researchers at Karolinska Institutet have developed a method based on artificial intelligence (AI) for the histopathologic diagnosis and grading of prostate cancer. The study, published by Ström et al in The Lancet Oncology, showed that the AI system can be trained to detect and grade prostate cancer from needle biopsy samples at a ranking comparable to that of international experts in prostate cancer pathology.

In a national cohort study conducted in the United Kingdom and reported in the Journal of Clinical Oncology, Nossiter et al found no clinically important differences in patient-reported functional outcomes among men receiving hypofractionated vs conventionally fractionated radiotherapy for nonmetastatic prostate cancer.

In the phase II TOPARP-B trial—reported by Mateo et al in The Lancet Oncology—investigators found that olaparib showed activity in men with metastatic castration-resistant prostate cancer and DNA damage response gene aberrations who had received one or two prior taxane regimens.

In a two-institute phase III trial reported in the Journal of Clinical Oncology, Malone et al found no difference in biochemical relapse-free survival with androgen-deprivation therapy (ADT) initiated prior to or concurrently with dose-escalated external-beam radiotherapy in patients with localized prostate cancer.

A study examining the differences in gene expression between African American and European American men with prostate cancer for three commercially available prostate cancer prognostic biomarker panels has found that these tests may not accurately predict cancer progression in African American patients. Because of the observed racial differences across the three panels for prostate cancer prognosis, caution is warranted when using these panels in clinical decision-making for African American patients. The study by Creed et al is published in Cancer Epidemiology, Biomarkers & Prevention.